CLAIMS

1. A solid form of the compound of formula (Id)



(Id)

wherein said solid form is selected from the group consisting of:

the dihydrate (DH1) characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 10.4, 11.6, 12.3, 13.1, 13.6, 14.3, 15.6, 16.0, 16.8, 18.5°;

the anhydrate (AH1) characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 8.5, 11.1, 12.4, 12.9, 15.6, 16.7, 18.9, 19.3, 20.0, 21.2°;

the heptahydrate (HH) characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 7.0, 8.6, 10.2, 11.1, 11.9, 13.4, 14.0, 14.5, 17.0, 17.4°;

the Form A characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 7.6, 9.5, 10.0, 11.2, 12.0, 14.3, 14.6, 15.3, 15.5, 19.3°;

the Form B characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 7.6, 9.0, 10.9, 12.3, 14.3, 15.0, 21.5, 22.1, 22.6, 23.7°;

the Form C characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 7.5, 8.1, 10.3, 12.6, 13.5, 13.8, 14.9, 17.5, 18.5, 20.6°;

the Monohydrate (MH1) characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at

the following 2θ -angles ± 0.2° 2θ: 9.2, 10.2, 11.8, 12.6, 13.6, 15.7, 16.0, 16.5, 17.5, 18.1°;

the potassium salt (K^+ salt) characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 3.0, 9.0, 12.6, 13.6, 15.0, 17.1, 18.0, 18.4, 18.8, 19.4°;

the sodium salt (Na^+ salt) form 1 characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 5.9, 8.9, 11.9, 12.8, 13.8, 14.9, 17.7, 18.6, 19.0 and 19.5°;

the Na^+ salt form 2 characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 5.6, 8.5, 12.6, 13.6, 14.1, 15.0, 16.7, 17.0, 18.8 and 19.8°;

the hydrochloride salt (HCl salt) characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 5.7, 7.3, 10.6, 13.3, 15.3, 15.4, 16.2, 20.1, 22.5, 23.0°;

and hydrobromide salt (HBr salt) characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks at the following 2θ -angles ± 0.2° 2θ: 12.5, 13.9, 14.5, 15.6, 18.6, 18.9, 19.8, 21.3, 22.0, 22.4°.

2. The solid form according to claim 1, wherein said solid form is selected from the group consisting of the dihydrate of compound (Id), the heptahydrate of compound (Id) and the potassium salt of the compound (Id).

3. The solid form according to any one of claims 1-2, wherein said solid form is the dihydrate or the potassium salt of the compound (Id).

4. The solid form according to any one of claims 1-3, wherein said solid form is the dihydrate characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles ± 0.2° 2θ :10.4, 11.6, 12.3 and 13.1 and 13.6°.

5. The solid form according to claim 4, wherein said x-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of peaks at the following 2θ-angles ± 0.2° 2θ: 14.3, 15.6, 16.0, 16.8 and 18.5°.

6. The solid form according to any one of claims 1-5, wherein said solid form is a crystal form characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ -angles ± 0.2° 2θ: 10.4, 11.6, 12.3, 13.1, 13.6, 14.3, 15.6, 16.0, 16.8 and 18.5°.

7. The solid form according to any one of claims 1-6, wherein said solid form is a crystal form characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ -angles± 0.2° 2θ: 12.3, 13.1, 13.6, 16.0, 16.8, 18.5, 18.9, 19.4, 20.5, 21.4, 23.5, 24.7, 25.4, 26.9 and 28.7°.

8. The solid form according to any one of claims 1-7, wherein said solid form is a crystal form characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) essentially as depicted in Figure 8a.

9. The solid form according to any one of claims 1-8, said solid form exhibiting a weight loss of 7.6% w/w compared to the initial weight when heated from 30°C to 150°C (heating rate 10°C/min), such as measured using thermogravimetric analysis.

10. The solid form according to claim 11, wherein said potassium salt has a crystal form characterized by an XRPD obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles ± 0.2° 2θ: 3.0, 9.0, 12.6, 13.6, and 15.0°.

11. The solid form according to claim 10, wherein said x-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of peaks at the following 2θ-angles ± 0.2° 2θ: 17.1, 18.0, 18.4, 18.8 and 19.4°.

12. The solid form according to any one of claims 1-3 and 10-11, wherein said potassium salt has a crystal form characterized by an XRPD obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles ± 0.2° 2θ: 3.0, 9.0, 12.6, 13.6, 15.0, 17.1, 18.0, 18.4, 18.8 and 19.4°.

13. The solid form according to claims 1-3, and 10-12, wherein said solid form has a crystal form characterized by an XRPD obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles ± 0.2° 2θ: 3.0, 9.0, 12.6, 13.6, 15.0, 18.0, 19.4, 21.8, 24.7, 27.1, 29.8, 33.3, 35.6, 38.6 and 39.6°.

14. The solid form according to any one of claims 1-3 and 10-13, said form exhibiting a weight loss of less than 1% w/w compared to the initial weight when heated from 20°C to 150°C (heating rate 10°C/min), such as measured using thermogravimetric analysis.

15. The solid form according to claims 1-2, wherein said solid form is a crystal form characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles ± 0.2° 2θ: 7.0, 8.6, 10.2, 11.1 and 11.9°.

16. The solid form according to any one of claims 1-2, and claim 15, wherein said x-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of peaks at the following 2θ-angles ± 0.2° 2θ: 13.4, 14.0, 14.5, 17.0 and 17.4°.

17. The solid form according to any one of claims 1-2, and claims 15-16, wherein said solid form is a crystal form characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles ± 0.2° 2θ: 7.0, 8.6, 10.2, 11.1, 11.9, 13.4, 14.0, 14.5, 17.0 and 17.4°.

18. The solid form according to any one of claims 1-2, and claims 15-17, wherein said solid form is a crystal form characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles ± 0.2° 2θ: 7.0, 8.6, 10.2, 11.1, 11.9, 14.0, 17.0, 22.2, 25.9, 27.3, 28.3, 30.8, 34.0, 34.8 and 35.2°.

19. The solid form according to any one of claims 1-2, and claims 15-18, wherein said solid form is a crystal form characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) essentially as depicted in Figure 10a.

20. The solid form according to any one of claims 1-2, and claims 15-19, exhibiting a weight loss of 21% w/w compared to the initial weight when heated from 20°C to 150°C (heating rate 10°C/min), such as measured using thermogravimetric analysis.

21. The solid form of the compound of formula (Id) according to any of claims 1-20, for use as a medicament.

22. A pharmaceutical composition comprising a therapeutically effective amount of the solid form of the compound of formula (Id) according to any one of claims 1-20, and one or more pharmaceutically acceptable excipients.

23. A solid form of the compound of formula (Id) according to any one of claims 1-20, for use in the treatment of a neurodegenerative disease or disorder such as Parkinson's Disease, Huntington’s disease, Restless leg syndrome or Alzheimer’s disease; or a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

24. Use of solid form of the compound of formula (Id) according to any one of claims 1-20, in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder such as Parkinson's Disease, Huntington’s disease, Restless leg syndrome or Alzheimer’s disease; or for the treatment of a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.